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Incidence – The number of new cases that develop over a given period of time. 




A couple – This refers to two people in an on-going sexual relationship; each of these people is 
referred to as a partner in the relationship. How individuals define their relationships will vary 
according to their cultural and social context. 





Epidemic – An outbreak of disease within a community or region. It may be seasonal, such as 
outbreaks of influenza and Ebola. 
Pandemic – An outbreak of a disease across different countries – or in global proportions. A 
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During my time working at various eye clinics in Kwazulu-Natal, I observed that more often 
than not, patients with disfiguring ocular surface squamous neoplasia (OSSN) were Human 
Immunodeficiency virus (HIV) positive and generally quite ill, often requiring radical 
ophthalmic surgery for the tumour and urgent referral to the local Centre for Disease control 
(CDC) and HIV/Acquired Immunodeficiency Syndrome (AIDS) clinics, whereas the patients 
with conjunctival intraepithelial neoplasia (CIN) were usually HIV negative or HIV positive but 
well looking. 
This sparked the question of whether or not there may be a relationship between Cluster of 
Differentiation 4: a glycoprotein found on the surface of immune cells (CD4) counts and OSSN 
in HIV positive patients and could these findings – should they be in the affirmative – be used as 
a CDC case defining criteria for AIDS and streamlet referral of these patients for Highly Active 
Antiretroviral Therapy (HAART). 
Although HIV/AIDS is a global pandemic and has been linked to OSSN, an extensive literature 
search found no studies specifically looking at CD4 counts in these patients. My study titled 
“Human Immunodeficiency Virus and CD4 count in ocular surface squamous neoplasia” was 
thus born. 
I elected to perform my study in two parts. Firstly a prospective descriptive study to determine 
the prevalence of HIV in OSSN in my study population from September 2012 to December 
2014, and secondly a case control study to determine the odds ratio of CD4 counts in HIV 
positive patients with OSSN (cases) and those without OSSN (controls) 
I hypothesized that:  
1.  >50% of patients with OSSN have HIV and  
2. At least 90% of HIV patients with OSSN have a CD4 count <350 cells/µl.  
It was unfortunate that the number of cases recruited in the given time fell short of the ideal 
number required as outlined in my protocol, however a minimum of 3 controls per case (as 
opposed to one) all matched for age and gender were selected from the national data base in 
order to improve the statistical significance and proceed with the study. 
I had hoped that the results from this study could be used to include OSSN as a CDC case 
defining condition for AIDS but unfortunately, although illustrative of the possibility, larger 
studies will have to be conducted to prove this. I was however, able to achieve the listed aims of 
the study and prove both of the hypotheses. It is hoped that in doing so, the holistic management 
of these patients with OSSN will be improved with their referral for HIV and AIDS screening 
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Part One: Introduction   
	
 
Ocular surface squamous cell neoplasia (OSSN) is the most frequently encountered conjunctival 
malignancy[1] and occurs more frequently in the tropics than in temperate regions[1]. Although 
the exact cause for OSSN is unknown, it has been found to be associated with increased 
ultraviolet exposure, Human papilloma virus (HPV) infection, Immunodeficiency syndrome, 
cigarette smoking, petroleum products, Caucasian decent and long standing inflammation. In fact 
it has been documented that patients with Acquired Immunodeficiency Syndrome (AIDS) have a 
13 fold increased risk of developing conjunctival epithelial malignancies and present at a 
younger age[2].    
With the association of ocular surface squamous neoplasia and human immunodeficiency virus 
(HIV), the high prevalence of HIV and the growing incidence of OSSN in HIV patients, it has 
become difficult to ignore the role HIV infection may play in the morbidity and mortality of 
patients with this tumour. 
Although most studies involving OSSN and HIV have been conducted in Africa an extensive 
literature search has found few studies looking specifically at Cluster of Differentiation 4: a 
glycoprotein found on the surface of immune cells (CD4) counts in these patients, with OSSN not 
included in the Expanded Case Definition for AIDS[3]. 
 
Background Epidemiology 
Since the advent of the HIV/AIDS epidemic in Sub Saharan Africa, the epidemiology of the 
disease appears to have changed dramatically with OSSN more often being diagnosed in younger 
women[4]. In one retrospective study examining clinical modalities for OSSN in Gaborone, 
Botswana from 1998-2008, it was found that the estimated annual incidence of OSSN in 
Botswana had risen from 0.13 cases per 100 000 (1.3 per 1 000 000) in 1993 to a peak of 7.6 per 
100 000 (76 per 1 000 000) in 2004[5]. Even though this was only an estimated incidence rate for 
OSSN, it is considered high for Sub Saharan Africa. Other countries in the region showed an 
incidence of 2.2 per 100 000 (22 per 1 000 000) persons in Tanzania and 2.1 per 100 000 (21 per 
1 000 000) in Uganda[5]. These differences in OSSN prevalence may mirror differences in HIV 
prevalence, with Botswana having an estimated adult HIV prevalence of 23.0, Tanzania 5.1 and 
Uganda 7.2[5]. 
Historically, the average incidence of OSSN of conjunctiva and cornea was estimated to be 
0.13/100 000 (1.3 per 1 000 000) in tribal groups in Uganda by Templeton in a study published 
in 1967, and 1.9/100 000 (19 per 1 000 000) population per year in the Brisbane metropolitan 
area of Australia by Lee in 1992[6]. Sun and co-workers reported an average incidence of 0.3 
million per year in the U.S in 1997[6]. Most recently in a study published in 2012, an incidence of 
37.3 per 10 000 000 (0.37 per 1 000 000) was reported for all eye cancers and 8.4 per 10 000 000 




adults with the average reported age being 56 years but cases have ranged from 4-96 years. 
Younger age of presentation of OSSN is seen among patients suffering from Xeroderma 
Pigmentosum and HIV infection[5]. 
In Africa there is a strong association between HIV and OSSN with the mean age of presentation 
for invasive OSSN from 32-37 years and the proportion of female patients ranges from 55-
70%[5]. Several studies have reported OSSN as the first clinical presentation of HIV in young 
patients and these tumours occurring in HIV patients are more aggressive and invasive, requiring 
enucleation or even exenteration[6], however minimal mention of CD4 counts were found in these 
studies. A retrospective cohort study conducted in Botswana from 1998-2008 only 180 (38.5%) 
HIV positive patients had CD4 counts available during the study period 85 (47.2%) had CD4 
counts <200 and 152 (84.4%) had CD4 counts <400 cells/µL[5]. Of the 85 patients with CD4 
counts <200 cells/µL at any time during the study period, 17 (20%) were on high dose 
antiretroviral therapy (HAART) prior to OSSN surgery, 13 (15.3%) were initiated on HAART 
within one year after surgery, 9 (10.6%) were initiated on HAART later in the study period and 
46 (54.1%) had no evidence of HAART initiation during the study period[5]. In another study of 
the review of literature in Sub Saharan Africa and published in Current Opinion 2010, it was 
found that the mean CD4 count level was significantly lower among patients with OSSN as 
compared to patients with other ocular pathologies[7]. 
With documented increasing incidence of OSSN in Sub Saharan Africa and the association with 
HIV as well as increased morbidity of these patients, I believe that the accessibility and initiation 
of HAART in this region may need further addressing. 
 
Treatment Guidelines  
HIV: - Currently, the Antiretroviral Treatment Guidelines for 2014 published by the South 
African HIV Clinicians Society in the 2014 December issue of the SAJHIVMED, states that all 
patients with CD4 counts <350 cells/µL should be advised and encouraged to start ART without 
delay[7]. If CD4 counts are between 350-500 cells/µL ART is recommended if the patient is ready 
and motivated to start[7]. ART is deferred if CD4 >500 cells/µL. ART is also recommended in 
WHO clinical stage 3 and 4 (see Appendix E and F), other severe HIV related disorders for 
example immune thrombocytopenia, thrombotic thrombocytopenic purpura, polymyositis and 
lymphocytic interstitial pneumonitis as well as non-HIV related disorders for example 
malignancies (excluding local malignancies), Hepatitis B co-infection, Hepatitis C co-infection. 
Having an HIV infected partner in a serodiscordant relationship is also important and ART is 
recommended in these patients regardless of CD4 count or clinical diagnosis. (See Figure 3). It is 
important to note that malignancies are listed under non-HIV related disorders and localized 
malignancies are excluded in the criteria for commencement of ART in South Africa despite 
evidence presented in a number of papers from Sub Saharan Africa that OSSN, a locally invasive 
malignancy, demonstrates a high morbidity in patients with HIV and is related to HIV infection 
and lower CD4 counts. 
To combat a potential social disaster in high burden countries, calls were made in 2003 to start 
the formidable task of getting ARVs to people who needed them[8]. Research conducted by 




South Africa would take more than five years to achieve[8]. Currently 54% of all people living 
with HIV in the region of East and Southern Africa are accessing ARVs[8]. Although ARV roll-
out is on the increase in South Africa it is still inadequate for the burden of the disease.  
OSSN: - Treatment of OSSN includes surgical excision alone, with or without additional 
adjunctive therapy. Resulting surface defects may need reconstruction with amniotic membrane 
transplantation, limbal stem cell grafts or skin grafts. Adjunctive therapies include cryotherapy, 
chemotherapy, radiotherapy, immune therapy, and amniotic membrane transplants to kill 
residual malignant cells at the excision margins or any that may have been seeded during 
excision and there are also reports of these being used as primary therapy15. In a Cochrane 
review by Gichuhi, quoting Shields et al it was found that advanced disease may require 
enucleation or exenteration to save a life[9]. 
 
Recurrence rates may be higher in Africa due to late presentation, exposure to solar radiation, 
and lack of many of the adjunctive therapies[9]. It is not clear whether the efficacy of these 
interventions is different in people with HIV infection or what the effects of HAART are on 
OSSN[9]. No randomised control trials of interventions currently used against conjunctival 
squamous cell carcinoma in HIV-infected individuals were identified[9]. 
 
 
Problem Statement and Aims 
Mittal et al reported in a study published by the Saudi Journal of Ophthalmology in 2013 that, in 
Africa, OSSN has been strongly associated with HIV[6]. HIV infection is now established as a 
risk factor for the development of squamous cell neoplasia of the conjunctiva based on studies 
from Rwanda, Malawi and Uganda[6] . A significant increase in the incidence of OSSN is also 
reported in patients with HIV/AIDS in the United States[6]. Thee are several studies that have 
reported OSSN as the first clinical presentation of HIV in young patients [6]. But an extensive 
literature search found no study specifically looking at CD4 counts in these patients. OSSN 
occurring in these patients are more aggressive and invasive requiring enucleation or even 
exenteration [6] thus showing significant morbidity and mortality in these patients. With the 
above problems highlighted in the literature, the aims of this two part study were to determine 
what percentage of patients with OSSN have HIV infection in our setting and to determine the 
odds ratio of HIV seropositivity with OSSN (from the cases), and patients without ocular surface 
squamous neoplasia (from the controls) specifically for CD4 counts <200 cells/µL, 200-350 
cells/µL and >350 cells/µL. 
 
Research Question and Purpose 
This study was to determine the prevalence of HIV in patients with OSSN in our setting and 
whether HIV positive patients are more likely to have a low CD4 count if they have OSSN, with 
the hypothesis, based on clinical experience, that more than 50% of patients with OSSN have 
HIV and at least 90% of HIV patients with OSSN have a CD4 count <350 cells/µL hence 




In 1981, the centres for Disease Control in the United States Department of Health and Human 
Services began surveillance for a newly recognized constellation of diseases, now termed 
Acquired Immunodeficiency Syndrome[10]. CDC developed a surveillance case definition for this 
syndrome in 1982 and received case reports directly from health care providers and state and 
local health departments[10] with the goals of AIDS surveillance to monitor trends in the number 
of  AIDS cases and monitor the scope of severe morbidity due to infection with Human 
Immunodeficiency Virus[10]. For example: - From 1980-1981 the CDC received its first reports 
of 5 cases involving homosexual males with Pneumocystis Carinii Pneumonia (PCP) due to 
severe immunodeficiency and by 1983, 51% of cases reported PCP without Kaposis sarcoma[10]. 
PCP was hence included as an opportunistic illness associated with this syndrome and remains a 
condition in the CDC’s expanded case definition for AIDS. 
The CDC case definition for AIDS was expanded in 1993[3]. It now includes all HIV infected 
persons who have a CD4 count of less that 200 cells/µL, or a recurrent pneumonia and invasive 
cervical cancer[3] and retains the 23 clinical conditions in the AIDS surveillance case definition 
published in 1987. The objectives of these changes are to simplify the classification of HIV 
infection, to reflect current standards of medical care for HIV infected persons, and to categorize 
more accurately, HIV related morbidity[3], thus more accurately reflect the number of persons 
with severe HIV related immunosuppression and those at higher risk for severe HIV related 
morbidity[3]. 
According to the Adult Antiretroviral Therapy Guidelines 2014, published by the South African 
HIV clinician’s society, all patients with a CD4 count <350 cells/µL should be advised and 
encouraged to start ART without delay. There is clinical evidence that this reduces mortality: a 
randomised trial in Haiti demonstrated reduced mortality and incident tuberculosis in patients 
starting ART at a CD4 count threshold of <350 cells/µL compared with patients waiting to 
commence therapy at a threshold of <200 cells/µL[7]. 
Currently OSSN is not included in the CDC expanded case definition for AIDS [See 
supplementary file Figure 4] and neither is it included in the guidelines for commencement of 
ART [See supplementary file Figure 3]. Despite this study not being powered to prove inclusion 
of OSSN in the expanded case definition for AIDS, it may be warranted that further, larger 
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Background                                                                 
Few studies have been done specifically looking at CD4 counts in patients with OSSN. Local 
clinical experience has suggested that there may in fact be a close relationship with OSSN and 
CD4 counts as more patients are seemingly presenting to our eye clinics with lower CD4 counts if 
they have this tumour as opposed to their OSSN naïve counterparts.         
Objectives                
The aims of this study were                    
1. To determine the prevalence of HIV in patients with OSSN.                      
2. To determine whether HIV positive patients are more likely to have a low CD4 count if they 
have OSSN, with the objective of including OSSN as a CDC case defining condition.      
Method                 
This study was conducted in two parts. First a prospective descriptive study to determine what 
percentage of patients with OSSN have HIV, and secondly a case control study to determine the 
odds ratio of HIV patients with OSSN and patients without OSSN for CD4 counts in the ranges 
of <200, 200 – 350 and >350 cells/µL. Statistical planning advised 105 cases and 210 controls.                                                                                                                                       
Results                    
Of the 13 cases collected, 100% were found to be HIV positive confirming the initial study 
hypothesis. 46% of cases were found to have a CD4 count <200 cells/µL, 46% a CD4 count 
between 200 – 350 cells/µL and 8% a CD4 count >350 cells/µL. Analysis of 6 000 controls 
showed an inverse relationship with the CD4 count – where a higher percentage of patients 
without OSSN had CD4 counts above 350 cells/µL at 56% compared to the 8% of cases with 
OSSN and 44% of patients without OSSN had CD4 counts <350 cells/µL compared to 92% of 
patients with tumour.                                                                                                    
Conclusion                        
Although a small study sample, this study highlights the association OSSN has with HIV and 
specifically with lower CD4 counts and the need for prompt antiretroviral treatment in these 
patients due to the high morbidity and mortality of these patients in the setting of HIV 
seropositivity. Larger studies are however recommended to ascertain if OSSN can indeed be 






Despite a number of studies regarding Ocular Surface Squamous Neoplasia (OSSN) and Human 
Immunodeficiency Virus (HIV) coming from Central and Sub Saharan Africa, few studies have 
specifically looked at Cluster of Differentiation 4: a glycoprotein found on the surface of 
immune cells (CD4) counts in these patients. This gap in literature, along with the clinical 
question of the apparent relationship of OSSN with HIV and CD4  count is what prompted this 
study. 
 
Background of Ocular Surface Squamous Neoplasia (OSSN) 
Clinically: - Squamous cell carcinoma of the conjunctiva is a rare, slow-growing tumour of the 
eye, normally affecting elderly men around 70 years of age. In Africa, however, the disease is 
different. The incidence is rising rapidly, affecting young persons (around 35 years of age), and 
usually affecting women. It is more aggressive with a mean history of three months at 
presentation. This pattern is related to the coexistence of the Human Immunodeficiency 
Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) pandemic, high Human Papilloma 
Virus (HPV) exposure, and solar radiation in the region. Various interventions exist, but despite 
therapy, there is a high recurrence rate (up to 43%) and poor cosmetic results in late disease[1].  
 
OSSN encompasses a spectrum of precancerous and cancerous lesions of the conjunctiva, from 
conjunctival intraepithelial neoplasia (CIN) to frankly invasive tumour with disfiguring orbital 
destruction and intracranial invasion although distant metastases are rare[2]. Patients usually 
present with redness, irritation, visual impairment, a mass of increasing size in the affected eye 
or sometimes may even be asymptomatic with the finding being incidental. Currently OSSN is 
the most common indication for exenteration performed in adults in Africa[3]. 
 
The tumour usually appears as a nodular or gelatinous plaque on the nasal corneal/conjunctival 
surface and maybe pigmented or not, often has a leukoplakic surface and prominent conjunctival 
feeder vessels. Most lesions are unilateral and can be mistaken for benign lesions for example, 
pterygium, pinguecula, or squamous papilloma. As mentioned progression of ocular surface 
squamous neoplasia is usually over weeks and months and is historically a slow growing tumour 
of elderly men living in areas of high ambient sunlight[4].  
Other risk factors known to be associated with ocular surface squamous neoplasia are infection 
with HPV types 16 and 18, smoking and HIV infection, ultra violet radiation exposure and other 
causes of immunosuppression. 
Epidemiologically: - An increase in the incidence of ocular surface squamous neoplasia since 






Figure 1: Image of the anterior ocular surface showing nodular gelatinous OSSN with large 




Figure 2: Image of the anterior ocular surface showing leukoplakic surface of OSSN 





Background of Human Immunodeficiency Virus (HIV) 
 
Clinically: - HIV Seroconversion presents as a flulike illness, consisting of fever, malaise and 
sometimes a generalized rash. Patients may also be asymptomatic. Generalized 
lymphadenopathy is common and may also be a presenting symptom. AIDS manifests with 
recurrent, severe and occasionally life threatening illnesses and/or opportunistic malignancies. 
The Human Immunodeficiency Virus itself does cause some sequelae, including AIDS-
associated dementia/encephalopathy and HIV wasting syndrome with chronic diarrhoea and 
weight loss[5]. 
This disease is spread in a number of identifiable ways, for example through unprotected 
intercourse with an infected partner, sharing intravenous drug paraphernalia, receipt of infected 
blood products, mucosal contact with infected blood or needle stick injuries, and maternal HIV 
infection which may cause infection in the new-born, infant or child if precautions are not 
taken[5]. 
 
Epidemiologically: - Although HIV and AIDS has become a global pandemic and global 
statistics as of December 2015 show an average of 36.7 million people living with HIV globally, 
19 million of these were living in Eastern and Southern Africa. (See Appendix F and G). In 
Eastern and Southern Africa, 10.3 million were accessing antiretroviral therapy, 54% (50-58) of 
all people living with HIV in the region (see Appendix F). HIV over the course of 35 years has 
infected 78 million people and killed 39 million people[6]. At present, a cure for this disease is 
still being sought[6]. The current Adult Antiretroviral Treatment Guidelines (2014) by the South 





















Expanded surveillance case definition for Acquired immunodeficiency syndrome 
(AIDS) 
The definition for AIDS includes all HIV-infected individuals with CD4 counts of <200 cells/µL 
(or CD4 percentage <14%) as well as those with specific HIV related conditions and symptoms[8] 
 




   Category B: Symptomatic conditions for adolescents or adults must meet one of the following 
criteria:- 
 
1. Must be attributed to HIV or indicate a defect in cell mediated immunity. 
2. Must be considered to have a clinical course or management that is complicated by HIV 
infection.  
Examples include, but are not limited to, the following: - Bacillary angiomatosis, oropharyngeal 
candidiasis (thrush), vulvovaginal candidiasis - persistent or resistant, pelvic inflammatory 
disease (PID), cervical dysplasia (moderate or severe)/cervical carcinoma in situ, hairy 
leukoplakia-oral, herpes zoster (shingles) - involving two or more episodes or at least one 
dermatome, idiopathic thrombocytopenic purpura, constitutional symptoms - fever (>38.5oC) OR 
diarrhoea lasting >1 month, peripheral neuropathy[9] 
 
 




  Category C: AIDS-indicator conditions       
Bacterial pneumonia, recurrent (two or more episodes in 12 months)                                                    
Candidiasis of the bronchi, trachea, or lungs                                                                                                
Candidiasis, oesophageal                                                                                                                                           
Cervical carcinoma, invasive, confirmed by biopsy                                                                            
Coccidiodomycosis, disseminated or extra pulmonary                                                                         
Cryptococcosis, extra pulmonary                                                                                                           
Cryptosporidiosis, chronic intestinal ( >1 month in duration )                                                                      
Cytomegalovirus disease (other than liver, spleen or nodes)                                                                         
Encephalopathy, HIV related                                                                                                                                    
Herpes simplex: chronic ulcers ( >1 month in duration ), or bronchitis, pneumonia, or esophagitis 
Histoplasmosis, disseminated or extra pulmonary                                                                                      
Isosporiasis, chronic intestinal ( >1 month in duration )                     
Kaposi sarcoma                                                                                                                                                   
Lymphoma, Burkett, immunoblastic, or primary central nervous system                                          
Mycobacterium avium complex (MAC) or Mycobacterium kansasii, disseminated or extra 
pulmonary                                                                                                                              
Mycobacterium tuberculosis, pulmonary or extra pulmonary                                                           
Mycobacterium, other species or unidentified species, disseminated or extra pulmonary          
Pneumocystis jiroveci (formerly carinii) pneumonia (PCP)                                                                            
Progressive multifocal leukoencephalopathy (PML)                                                                                      
Salmonella septicaemia, recurrent (non-typhoid)                                                                                   
Toxoplasmosis of brain                                                                                                   
Wasting syndrome caused by HIV (involuntary weight loss >10% of baseline body weight) 
associated with either chronic diarrhoea (two or more loose stools per day for >/= 1 month) or 









This research was conducted in two parts. 
PART 1: A prospective descriptive study with cases collected from September 2012 to 
December 2014  
PART 2: A case control study with cases recruited from part 1 and controls from the National 
Health Laboratory Services (NHLS). 
 
 
Study Procedure  
Inclusion criteria 
For Part 1, only new, adult patients from the eye clinics at approved sites with biopsy proven 
OSSN (ocular surface squamous neoplasia) and who consented to participation were to be 
included. Only the HIV positive portion of this group would serve as cases for the second part of 
the study. 
For Part 2, controls would be sourced from the national health laboratories database and matched 
for gender and age within 5 years of current age. Controls were to be tumour free and sourced 
from September 2012-2014. Patients from eye clinics and eye wards were excluded so as to 
negate accidental inclusion of patients with OSSN in the control group as the National Health 
Laboratories database did not have records of primary or ancilliary diagnoses for all patients. All 
patients that satisfied the criteria were entered into the study. All patients would be HIV positive 
and CD4 counts would be looked at. 
 
Data collection 
After statistical review of the recent literature during the protocol phase of the project, it was 
elected that the study should aim for 105 cases from part 1 and 210 controls in part 2, to be 
statistically significant based on the global incidence of OSSN. During part 2 of the study, 
patient results were sourced with the aid of convenient sampling, from the NHLS and matched 





Only OSSN treatment naïve, adult patients from approved sites, namely St Aidan's, Addington, 





Ethical considerations   
 
Data Management  
To maintain confidentiality during Part 1 of the study, a study questionnaire with a random study 
number was allocated to each patient at the time of data collection or admission for the recording 
of the required data. Only the attending doctor and myself as the principal investigator had 
access to the file and patient number that matched the study number. Anonymity was maintained 
during Part 2 of the study by using age within five years and gender. Patients from the eye clinic 
or eye ward were excluded and no names or other identifiers were used. 
 
Consent   
Patient consents for participation in the research and procedure of surgical tumour excision as 
well as the drawing of bloods was obtained prior to inclusion in the study. With the help of Ms 
Mary Gordon from the University of Kwazulu-Natal Humanities Department, consent forms 
were translated into isiZulu for those patients whose mother-tongue was isiZulu. Consent for Part 
2 was obtained from Dr B. Malope-Kgokong, the manager for the academic research corporate 
office to access the NHLS database for acquisition of the required controls. (See Appendix E) 
 
Biomedical Research Ethics Committee (BREC) approval               
Ethical approval was obtained from The Biomedical Research Ethics Committee of the 
University of KwaZulu-Natal. The ethics approval number allocated to the study was BE057/13. 




Data was recorded in Microsoft Excel and entered into Statistical Packages for the Social 
Sciences (SPSS) version 24. A p-value <0.05 was considered statistically significant. Descriptive 
statistical analysis of the data (means, standard deviations, ranges, frequencies and percentages) 
was initially conducted prior to conducting interferential statistics. A logistical regression was 









Overview of Results  
One of the aims of the study was to determine the prevalence of HIV in OSSN in our target 
population from September 2012 to December 2014 and although a smaller than required sample 
size was recruited due to poor data collection at the various approved hopsital sites with patients 
having to be excluded due to missing data, the following was found: - Of the 13 cases from Part 
1 of the study, 8 were female and 5 were male. 100% were HIV positive. See Table 1 below 
  
Table 1: An overview of results showing cases and controls 
         






Male Female With OSSN Without OSSN 
Number  5   8   13   6 030  
Tumour 100% 100% 100% 0% 
HIV+ 100% 100% 100% 100% 
HIV- 0% 0% 0% 0% 
      
Analysis of CD4 counts       
CD4 count categorization for HAART  
It was found that more patients (56%) had CD4 counts >350 cells/µL if they did not have OSSN 
with just 8% of patients with OSSN (cases) having a CD4 count >350 cells/µL. 46% of patients 
with OSSN had a CD4 count of between 200 – 350 cells/µL and 23% were without OSSN in this 
CD4 count range, with 46% of patients with OSSN also having a CD4 count of <200 cells/µL but 
just 21% of patients without OSSN in this range. See Table 2 below 
  
 Table 2: Analysis of CD4 count for HAART implementation in cases and controls 
 
Variable	CD4	
Count <200 200-350 >350 									Total
Count 1	292																				 1	421																				 3	443																				 6	156																				
%	without	OSSN 21% 23% 56% 100%
Count 6																										 6																										 1																										 13																									
%	with	OSSN 46% 46% 8% 100%
Count 1	298																				 1	427																				 3	444																				 6	169																				




Figure 5: Graph of CD4 counts relationship with OSSN versus without OSSN for the 
























A consolidated analysis of the CD4 count results showed that 92% of patients with OSSN had a 
CD4 count <350 cells/µL and only 44% of those without OSSN had CD4 counts <350 cells/µL. 
This supports the second aim of the study in determining whether patients who are HIV positive 
are more likely to have a lower CD4 count if they have OSSN. It was also found that 92% of 
patients had a CD4 count <350 cells/µL which is in support of the second hypoyhesis although it 
is to be noted that the sample size was smaller than required. See Figure 5 above. 
 
Logistic Regression 
The odds analysis of the data using cases against controls in the required CD4 count ranges 
found that patients with OSSN were 15.9 times more likely to have CD4 counts less than 200 
cells/µL than CD4 counts greater 350 cells/µL, and 14.5 times more likely to have CD4 counts in 
the range of 200-350 cells/µL than CD4 counts greater 350 cells/µL. This was found to be 
statistically significant with a greater than 95% confidence index. See Table 3 below. 
Table 3: Logistic regression to determine odds ratio as outlined in the protocol 
 
VARIABLE	CD	
COUNT ODDS	RATIO P	VALUE 95%	CI
<200 15.989																		 0.010																					 1.923-132,938
200-350 14.583																		 0.013																					 1.749-120,862






CD4 Count categorization for CDC expanded surveillance case definition for AIDS 
I have included the CD4 count categorization in HIV/AIDS. As previously mentioned AIDS is 
defined as a CD4 count <200 or the presence of certain category B or C AIDS defining 
conditions. It is interesting to note that 46% of patients with OSSN had a CD4 count <200 
cells/µL compared to just 21% of those without tumour. See Table 4 below 
 
Table 4: Analysis of CD4 counts in the CDC expanded case definition for AIDS CD4 














The Centre for Disease Control (CDC) Expanded Surveillance case definition for HIV/AIDS, 
since the advent of the disease in the United States in the early 1980s, has been revised several 
times to respond to diagnostic advances. Both the laboratory and the clinical criteria have 
evolved to include HIV “negative” individuals who may be in the window period and additional 
AIDS defining conditions for example: - invasive cervical cancer, recurrent pneumonia and 
pulmonary Mycobacterium Tuberculosis infection. The definition of AIDS includes all HIV 
infected individuals with CD4 counts <200 cells/µL (or CD4 percentage <14%) as well as those 
with certain HIV-related conditions and symptoms[8].                                             
Symptomatic conditions occur in the HIV infected adolescent or adult and should either be 
attributed to     
1. The HIV infection or indicate a defect in cell mediated immunity, or 
2. Have a clinical course or management that is complicated by HIV infection 
In this study it was found that 46% of patients had a CD4 count <200 cells/µL. This aligns with 
other studies conducted in the region. For example, in a study conducted in sub Saharan Africa, 
the median CD4 count within one year of OSSN surgery was 192 cells/µL (IQR 122-288) and 
more than half of the OSSN patients had CD4 counts <200 cells/µL, consistent with a diagnosis 
of AIDS[10]. A recent study from Tanzania reported that 85% of OSSN patients had CD4 counts 
<200 cells/µL and the median CD4 count of patients at the time of presentation was 71 
cells/µL[10]. Similarly in Uganda, the median CD4 count among HIV-infected OSSN patients was 
111 cells/µL (IQR 62-221) and 65% of HIV-infected OSSN patients died of AIDS related 
complications at a median of 20 months after OSSN diagnosis[10]. Although these studies allude 
to the fact that there is a linear relationship between CD4 count and OSSN, these could be 
incidental findings. The association with HIV suggests that immunosuppression plays a role in 
OSSN; however, a linear association between CD4 lymphocyte count and OSSN has not been 
confirmed[11].  
 
Although this study did not look at the grades of OSSN as well as the course and outcome for 
patients with CD4 counts in the different categories, it was a general observation that those 
patients with more invasive OSSN and requiring more radical ophthalmic surgery for the 
removal of tumour were indeed more ill in terms of their HIV progression. It has been shown in 
a review article published in Current Opinion Oncology 2010, September that data from Uganda, 
in which the recurrence rate after a median follow up of 32 months (range 0-81) was 3.2%[4]. 
64% of these patients were HIV seropositive. It was also stated in the same paper that OSSN 
appears to be more aggressive in the setting of HIV disease. In another study conducted in 
Malawi it was found that OSSN was indeed the first presenting symptom for HIV in the majority 
of the study patients[9]. It does however remain a fact that an extensive literature search, to my 
knowledge, has found no study specifically looking at CD4 counts in OSSN with morbidity and 
mortality in these patients and it is hence a recommendation that this warrants more 
investigation. 
It is a limitation of my study that OSSN is in fact a rare tumour as far as ocular tumours go but 




there have been other papers with evidence to support the association of HIV with OSSN thus 
supporting the need for a holistic approach to the management of these patients. In fact, in one 
study that may be regarded as supportive to mine, conducted in Harare, Zimbabwe, it was clearly 
stated in its recommendations that OSSN is an HIV/AIDS defining tumour in regions 
experiencing an HIV/AIDS epidemic[12]. Patients with OSSN fit in the WHO stage 3 and 4 of 
HIV/AIDS disease and can be started on antiretroviral therapy without a CD4 count if the test is 
not readily available[12].  
Although the CDC expanded surveillance case definition for AIDS is specific in its criteria and 
currently does not include OSSN as either a category B-symptomatic or category C-clinical 
condition[7], evidence presented from papers originating mostly in Sub Saharan Africa, suggest 
that OSSN be further investigated for inclusion in the CDC Expanded Surveillance Case 
definition for AIDS. 
Squamaous cell carcinoma of the conjunctiva has been shown to be a marker of HIV 
seropositivity or AIDS[13] and it is hoped that more comprehensive studies be conducted to 
thoroughly investigate the relationship of OSSN and CD4 counts in HIV positive patients with a 






This study, despite small sample size, found that more than 50% of patients with OSSN will be 
HIV positive and more than 90% of HIV positive patients with OSSN having CD4 counts <350 
cells/µL. Significant knowledge gaps have been highlighted with regards to OSSN and CD4 
counts in HIV positive patients with no published studies looking at these vaiables. The current 
literature reitterates the asociation of OSSN with HIV with some studies proving OSSN as the 
initial presenting feature for HIV/AIDS. Escalation of the morbidity of OSSN on the background 
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I	 understand	 and	 accept	 that	 I	 will	 be	 required	 to	 submit	 half-yearly	 progress	 reports	 for	
pharmaceutical	 studies	and	annual	 reports	 for	other	 studies.	 	Where	applicable,	all	 reports	 from	the	







I	 agree	 to	 abide	 by	 the	 guidance	 contained	 in	 the	 SA	 Department	 of	 Health	 (2004)	 Ethics	 in	 Health	
Research:	 Principles,	 structures	 and	 processes	 and	 the	 (2006)	 South	 African	 Good	 Clinical	 Practice	
Guidelines	 and	 the	 UKZN	 Terms	 of	 Reference	 and	 Standard	 Operating	 Procedures	 of	 the	 UKZN	
Biomedical	 Research	 Ethics	 Committee.	 All	 are	 available	 at	
http://research.ukzn.ac.za/ResearchEthics11415.aspx		
	
I	 understand	 and	 accept	 that	 all	 information	 pertaining	 to	 this	 application	 is	 a	 true	 reflection	 of	 the	
project	proposed	and	I	take	full	responsibility	should	there	be	any	transgression.	
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Appendix B – Guidelines for Authorship  
 	
General article format/layout 
Accepted manuscripts that are not in the correct format specified 
in these guidelines will be returned to the author(s) for 
correction, which will delay publication. 
  
General: 
• Manuscripts must be written in UK English. 
• The manuscript must be in Microsoft Word or RTF document 
format. Text must be single-spaced, in 12-point Times New 
Roman font, and contain no unnecessary formatting (such as 
text in boxes). 
• Please make your article concise, even if it is below the word 
limit. 
• Qualifications, full affiliation (department, school/faculty, 
institution, city, country) and contact details of ALL authors 
must be provided in the manuscript and in the online 
submission process.  
• Abbreviations should be spelt out when first used and thereafter 
used consistently, e.g. 'intravenous (IV)' or 'Department of 
Health (DoH)'. 
• Scientific measurements must be expressed in SI units except: 
blood pressure (mmHg) and haemoglobin (g/dL). 
• Litres is denoted with an uppercase L e.g. 'mL' for millilitres). 
• Units should be preceded by a space (except for % and ºC), e.g. 
'40 kg' and '20 cm' but '50%' and '19ºC'. 
• Please be sure to insert proper symbols e.g. µ not u for micro, a 
not a for alpha, b not B for beta, etc. 
• Numbers should be written as grouped per thousand-units, i.e. 4 
000, 22 160. 
• Quotes should be placed in single quotation marks: i.e. The 
respondent stated: '...' 




square brackets, which are reserved for denoting 
concentrations or insertions in direct quotes. 
• If you wish material to be in a box, simply indicate this in the 
text. You may use the table format –this is the only 
exception. Please DO NOT use fill, format lines and so on. 
   
Research 
Guideline word limit: 4 000 words 
  
Research articles describe the background, methods, results and 
conclusions of an original research study. The article should 
contain the following sections: introduction, methods, results, 
discussion and conclusion, and should include a structured 
abstract (see below). The introduction should be concise – no 
more than three paragraphs – on the background to the research 
question, and must include references to other relevant published 
studies that clearly lay out the rationale for conducting the study. 
Some common reasons for conducting a study are: to fill a gap in 
the literature, a logical extension of previous work, or to answer 
an important clinical question. If other papers related to the same 
study have been published previously, please make sure to refer 
to them specifically. Describe the study methods in as much detail 
as possible so that others would be able to replicate the study 
should they need to. Results should describe the study sample as 
well as the findings from the study itself, but all interpretation of 
findings must be kept in the discussion section, which should 
consider primary outcomes first before any secondary or tertiary 
findings or post-hoc analyses. The conclusion should briefly 
summarise the main message of the paper and provide 
recommendations for further study. 
  
Select figures and tables for your paper carefully and sparingly. 
Use only those figures that provided added value to the paper, 




Do not replicate data in tables and in text. 
  
Structured abstract 
• This should be 250-400 words, with the following recommended 
headings: 
◦ Background: why the study is being done and how it 
relates to other published work. 
◦ Objectives: what the study intends to find out 
◦ Methods: must include study design, number of 
participants, description of the intervention, primary 
and secondary outcomes, any specific analyses that 
were done on the data. 
◦ Results: first sentence must be brief population and 
sample description; outline the results according to the 
methods described. Primary outcomes must be 
described first, even if they are not the most significant 
findings of the study. 
◦ Conclusion: must be supported by the data, include 
recommendations for further study/actions. 
• Please ensure that the structured abstract is complete, accurate 
and clear and has been approved by all authors. 
• Do not include any references in the abstracts. 
  
   
Main article 
All articles are to include the following main sections: 
Introduction/Background, Methods, Results, Discussion, 
Conclusions. 
The following are additional heading or section options that may 
appear within these: 
• Objectives (within Introduction/Background): a clear statement 
of the main aim of the study and the major hypothesis tested 
or research question posed 
• Design (within Methods): including factors such as prospective, 
randomisation, blinding, placebo control, case control, 
crossover, criterion standards for diagnostic tests, etc. 




number of participating centres. 
• Participants (instead of patients or subjects; within Methods): 
numbers entering and completing the study, sex, age and 
any other biological, behavioural, social or cultural factors 
(e.g. smoking status, socioeconomic group, educational 
attainment, co-existing disease indicators, etc)that may 
have an impact on the study results. Clearly define how 
participants were enrolled, and describe selection and 
exclusion criteria. 
• Interventions (within Methods): what, how, when and for how 
long. Typically for randomised controlled trials, crossover 
trials, and before and after studies. 
• Main outcome measures (within Methods): those as planned in 
the protocol, and those ultimately measured. Explain 
differences, if any. 
  
Results 
• Start with description of the population and sample. Include key 
characteristics of comparison groups. 
• Main results with (for quantitative studies) 95% confidence 
intervals and, where appropriate, the exact level of 
statistical significance and the number need to treat/harm. 
Whenever possible, state absolute rather than relative risks. 
• Do not replicate data in tables and in text. 
• If presenting mean and standard deviations, specify this clearly. 
Our house style is to present this as follows: 
• E.g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not 
use the ± symbol for mean (SD). 
• Leave interpretation to the Discussion section. The Results 




Please ensure that the discussion is concise and follows this 
overall structure – sub-headings are not needed: 
• Statement of principal findings 
• Strengths and weaknesses of the study 
• Contribution to the body of knowledge 




• The meaning of the study – e.g. what this study means to 
clinicians and policymakers 




This may be the only section readers look at, therefore write it 
carefully. Include primary conclusions and their implications, 
suggesting areas for further research if appropriate. Do not go 
beyond the data in the article. 
   
Illustrations/photos/scans 
• If illustrations submitted have been published elsewhere, the 
author(s) should provide consent to republication obtained 
from the copyright holder.  
• Figures must be numbered in Arabic numerals and referred to in 
the text e.g. '(Fig. 1)'. 
• Each figure must have a caption/legend: Fig. 1. Description (any 
abbreviations in full). 
• All images must be of high enough resolution/quality for print. 
• All illustrations (graphs, diagrams, charts, etc.) must be in PDF 
form. Ensure all graph axes are labelled appropriately, with a 
heading/description and units (as necessary) indicated. Do 
not include decimal places if not necessary e.g. 0; 1.0; 2.0; 
3.0; 4.0 etc. 
• Scans/photos showing a specific feature e.g. Intermediate 
magnification micrograph of a low malignant potential (LMP) 
mucinous ovarian tumour. (HandE stain). –include an arrow 
to show the tumour. 
• Each image must be attached individually as a 'supplementary 
file' upon submission (not solely embedded in the 





• Tables should be constructed carefully and simply for intelligible 
data representation. Unnecessarily complicated tables are 
strongly discouraged. 
• Embed/include each table in the manuscript Word file - do not 
provide separately as supplementary files. 
• Number each table in Arabic numerals (Table 1, Table 2, etc.) 
and refer to consecutively in the text. 
• Tables must be cell-based (i.e. not constructed with text boxes 
or tabs) and editable. 
• Ensure each table has a concise title and column headings, and 
include units where necessary. 
• Footnotes must be indicated with consecutive use of the 
following symbols: * † ‡ § ¶ || then ** †† ‡‡ etc. 
  
Do not: Use [Enter] within a row to make ‘new rows’: 
Rather: 
Each row of data must have its own proper row: 
Do not: use separate columns for n and %: 
Rather: 
Combine into one column, n (%): 
Do not: have overlapping categories, e.g.: 
Rather: 








NB: Only complete, correctly formatted reference lists in 
Vancouver style will be accepted. Reference lists must be 
generated manually and not with the use of reference manager 
software. Endnotes must not be used. Authors must verify 
references from original sources. 
• Citations should be inserted in the text as superscript numbers 
between square brackets, e.g. These regulations are 
endorsed by the World Health Organization,[2] and others.[3,4-
6] 
• All references should be listed at the end of the article in 
numerical order of appearance in the Vancouver style (not 
alphabetical order). 
• Approved abbreviations of journal titles must be used; see the 
List	of	Journals	in	Index	Medicus. 
• Names and initials of all authors should be given; if there are 
more than six authors, the first three names should be given 
followed by et al. 
• Volume and issue numbers should be given. 
• First and last page, in full, should be given e.g.: 1215-1217 not 
1215-17. 
• Wherever possible, references must be accompanied by a digital 
object identifier (DOI) link). Authors are encouraged to use 
the DOI lookup service offered by CrossRef: 
◦ On the Crossref homepage, paste the article title into the 
‘Metadata search’ box. 
◦ Look for the correct, matching article in the list of results. 
◦ Click Actions > Cite 
◦ Copy the DOI between { }, which will always start with 10. 
◦ Provide as follows: DOI:10.7196/07294.937.98x 
  
Some examples: 
• Journal references: Price NC, Jacobs NN, Roberts DA, et al. 
Importance of asking about glaucoma. Stat Med 
1998;289(1):350-355. DOI:10.1000/hgjr.182 
• Book references: Jeffcoate N. Principles of Gynaecology. 4th ed. 
London: Butterworth, 1975:96-101. 
• Chapter/section in a book: Weinstein L, Swartz MN. Pathogenic 




Sodeman WA, eds. Pathologic Physiology: Mechanisms of 
Disease. Philadelphia: WB Saunders, 1974:457-472. 
• Internet references: World Health Organization. The World 
Health Report 2002 - Reducing Risks, Promoting Healthy 
Life. Geneva: WHO, 2002. http://www.who.int/whr/2002 
(accessed 16 January 2010). 
• Legal references 
•              Government Gazettes: 
National Department of Health, South Africa. National Policy for 
Health Act, 1990 (Act No. 116 of 1990). Free primary health care 
services. Government Gazette No. 17507:1514. 1996. 
In this example, 17507 is the Gazette Number. This is followed by 
:1514 - this is the notice number in this Gazette. 
•              Provincial Gazettes: 
Gauteng Province, South Africa; Department of Agriculture, 
Conservation, Environment and Land Affairs. Publication of the 
Gauteng health care waste management draft regulations. 
Gauteng Provincial Gazette No. 373:3003, 2003. 
•              Acts: 
South Africa. National Health Act No. 61 of 2003. 
•              Regulations to an Act: 
South Africa. National Health Act of 2003. Regulations: Rendering 
of clinical forensic medicine services. Government Gazette No. 
35099, 2012. (Published under Government Notice R176). 
•              Bills: 
South Africa. Traditional Health Practitioners Bill, No. B66B-2003, 
2006. 
•              Green/white papers: 
South Africa. Department of Health Green Paper: National Health 




•              Case law: 
Rex v Jopp and Another 1949 (4) SA 11 (N) 
Rex v Jopp and Another:  Name of the parties concerned 
1949: Date of decision (or when the case was heard) 
(4): Volume number 
SA: SA Law Reports 
11: Page or section number 
(N): In this case Natal - where the case was heard. Similarly, (C) 
woud indicate Cape, (G) Gauteng, and so on. 
NOTE: no . after the v 
• Other references (e.g. reports) should follow the same format: 
Author(s). Title. Publisher place: Publisher name, year; 
pages. 
• Cited manuscripts that have been accepted but not yet 
published can be included as references followed by '(in 
press)'. 
• Unpublished observations and personal communications in the 
text must not appear in the reference list. The full name of 
the source person must be provided for personal 





Submission Preparation Checklist 
 
As part of the submission process, authors are required to check 
off their submission's compliance with all of the following items, 
and submissions may be returned to authors that do not adhere 
to these guidelines. 
 
1 Named authors consent to publication and meet the 
requirements of authorship as set out by the journal. 
2 The submission has not been previously published, nor is it 
before another journal for consideration. 
3 The text complies with the stylistic and bibliographic 
requirements in Author Guidelines. 
4 The manuscript is in Microsoft Word or RTF document 
format. The text is single-spaced, in 12-point Times New 
Roman font, and contains no unnecessary formatting. 
5 Illustrations/figures are high resolution/quality (not 
compressed) and in an acceptable format (preferably TIFF or 
PNG). These must be submitted individually as 
'supplementary files' (not solely embedded in the 
manuscript). 
6 For illustrations/figures or tables that have been published 
elsewhere, the author has obtained written consent to 
republication from the copyright holder. 
7 Where possible, references are accompanied by a digital 
object identifier (DOI) and PubMed ID (PMID)/PubMed 
Central ID (PMCID). 
8 An abstract has been included where applicable. 
9 The research was approved by a Research Ethics Committee 
(if applicable) 
10 Any conflict of interest (or competing interests) is indicated 
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Appendix J – Raw Data  
Page 1 of 6 056 controls – Full list available on request 
AGE_TESTED_YEARS GENDER PROVINCE_NAME FACILITY_NAME WARD_NAME HIV_STATUS CD4_COUNT OSSN ARVs
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 304 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 628 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 239 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL WARD	NOT	STATED POSITIVE 979 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL 7F	PAEDIATRIC	WARD POSITIVE 756 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL OCC	HEALTH	&	SAFETY	(STAFF	CLINIC) POSITIVE 1006 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 48 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 520 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 453 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 217 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 445 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL 7F	PAEDIATRIC	WARD POSITIVE 947 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 173 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 394 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 308 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 402 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 817 N U
24 F KWAZULU-NATAL GREY'S	HOSPITAL H2	MEDICAL	WARD POSITIVE 707 N U
24 F KWAZULU-NATAL GREY'S	HOSPITAL CDC	CLINIC POSITIVE 282 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 359 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CRISIS	CENTRE POSITIVE 572 N U
24 F KWAZULU-NATAL GREY'S	HOSPITAL M4	OBSTETRICS	AND	GYNAECOLOGY	WARD POSITIVE 134 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 370 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 284 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 245 N U
24 F KWAZULU-NATAL GREY'S	HOSPITAL RENAL	UNIT	D2 POSITIVE 1506 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 480 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 595 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL WARD	NOT	STATED POSITIVE 682 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 5 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL 5B1	FEMALE	MEDICAL	WARD POSITIVE 616 N U
24 F KWAZULU-NATAL GREY'S	HOSPITAL MEDICAL	ADMISSIONS	WARD POSITIVE 900 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 430 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL WARD	NOT	STATED POSITIVE 482 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL WARD	NOT	STATED POSITIVE 443 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 437 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 979 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL MEDICAL	OPD POSITIVE 115 N U
24 F KWAZULU-NATAL GREY'S	HOSPITAL E1	PAEDIATRIC	WARD POSITIVE 647 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 523 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 500 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL OCC	HEALTH	&	SAFETY	(STAFF	CLINIC) POSITIVE 194 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL TEEN	CLINIC POSITIVE 469 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 540 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 332 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL 5B1	FEMALE	MEDICAL	WARD POSITIVE 2 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 530 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 463 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 631 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 178 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL 7F	PAEDIATRIC	WARD POSITIVE 525 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 707 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 295 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 161 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 830 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 686 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL 5B1	FEMALE	MEDICAL	WARD POSITIVE 2 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 444 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CRISIS	CENTRE POSITIVE 427 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 684 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 462 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 598 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL B	WARD POSITIVE 80 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 311 N U
24 F KWAZULU-NATAL GREY'S	HOSPITAL E1	PAEDIATRIC	WARD POSITIVE 460 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 542 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL CDC	CLINIC POSITIVE 22 N U
24 F KWAZULU-NATAL EDENDALE	HOSPITAL WARD	NOT	STATED POSITIVE 782 N U





Page 1 – Showing 13 Cases 
	
AGE_TESTED_YEARS GENDER PROVINCE_NAME FACILITY_NAME WARD_NAME HIV_STATUS CD4_COUNT OSSN ARVs
43 M KWAZULU-NATAL SAH EYE	CLINIC POSITIVE 124 YES YES
39 M KWAZULU-NATAL SAH EYE	CLINIC POSITIVE 251 YES YES
34 F KWAZULU-NATAL ADH EYE	CLINIC POSITIVE 45 YES YES
44 F KWAZULU-NATAL GREYS EYE	CLINIC POSITIVE 243 YES YES
31 M KWAZULU-NATAL GREYS EYE	CLINIC POSITIVE 303 YES NO
31 F KWAZULU-NATAL GREYS EYE	CLINIC POSITIVE 277 YES NO
39 M KWAZULU-NATAL GREYS EYE	CLINIC POSITIVE 241 YES YES
49 F KWAZULU-NATAL GREYS EYE	CLINIC POSITIVE 444 YES YES
44 F KWAZULU-NATAL GREYS EYE	CLINIC POSITIVE 195 YES YES
32 F KWAZULU-NATAL GREYS EYE	CLINIC POSITIVE 43 YES YES
28 F KWAZULU-NATAL EDH EYE	CLINIC POSITIVE 181 YES U
41 F KWAZULU-NATAL EDH EYE	CLINIC POSITIVE 101 YES NO





















Appendix K – Abbreviations and acronyms 
	
AIDS  Acquired Immunodeficiency Syndrome 
ART  Antiretroviral Therapy 
ARV   Antiretroviral  
CD4  Cluster of Differentiation 4: a glycoprotein found on the surface of immune cells 
CIN  Conjunctival intraepithelial neoplasia 
CDC    Centre for Disease Control 
HAART  Highly Active Antiretroviral Therapy 
HIV  Human Immunodeficiency Virus 
HPV  Human Papilloma Virus 
NHLS  National Health Laboratory Service 
TB  Tuberculosis 
UKZN   University of KwaZulu-Natal 
WHO  World Health Organization 


















Figure 3: ART Recommendations by the South African HIV clinicians society[6] 
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Figure	4:	Clinical	categories	for	HIV/AIDS[7]	
	
	
	
